

SKYEPHARMA PLC
Form 6-K
May 08, 2006

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of May, 2006

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

Edgar Filing: SKYEPHARMA PLC - Form 6-K

SkyePharma PLC

SkyePharma and Kos to Host Teleconference Today on US Marketing and Distribution Agreement for Flutiform

LONDON, ENGLAND, 8 May, 2006 -- SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) and Kos Pharmaceuticals, a joint teleconference later today to discuss the US development and marketing agreement for SkyePharma's Chief Executive, Frank Condella, and Adrian Adams, President and Chief Executive Officer. The teleconference will provide information on the collaboration including information on each company's capabilities in the field.

The conference call will be at 1330 BST / 0830 EDT today. The conference call will be available on the website of either company at www.kospharm.com or www.skyepharma.com where the presentation will be available. Please go to the respective website at least fifteen minutes prior to the call to register, download the presentation software. Those who cannot access the webcast can participate by telephone by calling +1-913-312-1234. A replay will also be available on both websites or by calling +1-719-457-0820 and entering code 123456789 today until 2359 EDT on Friday, May 12, 2006.

For further information please contact:

SkyePharma PLC +44 207 491 1777
Frank Condella, Chief Executive Officer
Peter Laing, Director of Corporate Communications +44 207 491 5124

Sandra Haughton, US Investor Relations +1 212 753 5780

Buchanan Communications +44 207 466 5000
Tim Anderson / Mark Court / Rebecca Skye Dietrich

Notes for editors

About SkyePharma

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies and more effective drug formulations. There are now twelve approved products incorporating SkyePharma's oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, please visit www.skyepharma.com.

Certain statements in this news release are forward-looking statements and are made in reliance upon the U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectations expressed in these statements are reasonable, it can give no assurance that these expectations will materialize. Because of the many risks and uncertainties, actual results may vary significantly from those expressed or implied by the forward-looking statements. These risks are based upon a number of factors, which are described in SkyePharma's 20-F and other documents on file with the SEC. These factors may cause differences between actual results and those implied by the forward-looking statements. Without limitation, risks related to the development of new products, risks related to obtaining regulatory approval for existing, new or expanded indications of existing and new products, risks related to SkyePharma's ability to maintain or expand market share on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability to maintain or expand market share in the face of changes in customer requirements, competition and regulatory compliance, the risk of product liability claims, risks related to the ownership of intellectual property, risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to update or revise any forward-looking statement to reflect events or circumstances after the date of this release.

END

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill

Title: Company Secretary

Date: May 8, 2006